7-country WION report puts UAE controlled-medicine controls on COO agenda

WION's 8 September 2025 report on drug penalties in 7 countries puts a practical UAE issue in view: controlled-medicine failures can trigger licence scrutiny, cancelled procedures and legal review.

The highest-stakes readers are COOs, medical directors, pharmacy leaders and compliance officers. A hospital, clinic, pharmacy or drug store can hold a valid licence from the Dubai Health Authority (DHA), Department of Health Abu Dhabi (DOH) or Ministry of Health and Prevention (MOHAP) and still face exposure if prescribing, storage, dispensing or patient import records are weak.

Why UAE operators should care

The UAE framework sits under Federal Decree-Law No. 30 of 2021 on combating narcotics and psychotropic substances, which took effect on 2 January 2022. MOHAP's legislation page says the law was amended by Federal Decree-Law No. 14 of 2025. For providers, that makes controlled-medicine governance current work for services that handle restricted analgesics, sedatives, stimulants or psychiatric medicines.

“The UAE has a zero-tolerance policy for recreational use of drugs.”

— The Official Portal of the UAE Government

For operators, the practical point is narrower than the criminal penalties in WION's article. The same legal category that captures illicit use also affects legitimate care pathways. Pain management, oncology, anaesthesia, emergency medicine, psychiatry and addiction treatment all depend on controlled products moving through auditable clinical systems.

The control work sits inside operations

DOH's standard for narcotics, psychotropic and semi-controlled medicinal products requires licensed facilities in Abu Dhabi to assign a responsible person in charge, either a licensed physician or pharmacist. DOH also requires written policies and standard operating procedures. That makes the issue a COO task, a pharmacy governance task and a medical director liability task.

DHA pharmacy guidelines apply to DHA-licensed pharmacies in Dubai, including hospital, community, government, semi-government, private and free-zone settings. DHA says the purpose is compliance with federal laws and local regulations on narcotics, controlled and semi-controlled drugs. For Dubai operators, pharmacy policy has to connect with facility licensing, clinical governance and inspection readiness.

• 1 federal baseline: Federal Decree-Law No. 30 of 2021 governs narcotics and psychotropic substances nationally.
• 1 current amendment: Federal Decree-Law No. 14 of 2025 updates parts of the 2021 framework.
• 3 regulator interfaces: DHA in Dubai, DOH in Abu Dhabi and Al Ain, and MOHAP for federal regulation and the Northern Emirates.
• 2 accountable roles: a licensed physician or pharmacist should own controlled-medicine governance where the local standard requires it.

CFOs should treat the issue as downside risk. The cost is rarely the stock value of the medicine. The larger exposure is service interruption, licence review, legal fees, cancelled procedures and reputational damage if controlled products are missing, expired, poorly recorded or dispensed outside approved processes.

Where scrutiny may land next

For CIOs, the weak point is often documentation across systems. Electronic medical records, pharmacy systems, inventory modules and incident reporting tools need one audit trail for prescribing, dispensing, administration, wastage and return. A manual drug register may satisfy one control while leaving gaps in reconciliation.

Medical directors have a separate risk. Access rules must protect legitimate treatment. Overly restrictive internal policies can delay acute pain care, oncology care or psychiatric care. Loose controls create legal exposure. Facility policy should name who may prescribe, who may approve exceptions, how stock counts are reconciled and how suspected diversion is escalated within 24 hours.

The takeaway for executives is concrete: use Q4 2025 to review controlled-medicine SOPs, responsible-person appointments, stock reconciliation, patient import documentation and incident escalation. The next regulator inspection or accreditation cycle can turn a paperwork gap into a licensing problem.